Document Detail

Cardiovascular safety of anti-TNF-alpha therapies: Facts and unsettled issues.
MedLine Citation:
PMID:  21539939     Owner:  NLM     Status:  Publisher    
Tumor necrosis factor alpha (TNFa) plays a central role in the pathogenesis of both rheumatoid arthritis (RA) and heart failure (HF). Over the last years RA could benefit from TNFa inhibitors that mitigated disease activity, decreased structural damage, and prevented cardiovascular events. Contraindications to clinical use of TNFa inhibitors may include infections, autoimmune disorders, demyelinating disease, cancer, and heart failure. Overall, these pathological conditions do not appear to increase significantly during treatment with TNFa antagonists compared to placebo. Clinical trials probed these drugs in non RA HF patients produced disappointing results and formed the basis to contraindicate TNFa inhibitors in patients with moderate-severe HF. Although National Registries provide apparently encouraging data about HF safety of anti-TNFa therapies, they cannot adequately assess the actual risk, as these drugs are administered to patients with no cardiac dysfunction. These findings introduced a "rheumatological dilemma" in the clinical management of RA with anti-TNFa. Probably, in RA patients anti-TNFa agents would intercept TNFa and prevent its toxic effects on heart function, while in patients with advanced heart damage (NYHA class III-IV HF), anti-TNFa agents would interfere with the beneficial preconditioning effects of TNFa.
Cacciapaglia Fabio; Navarini Luca; Menna Pierantonio; Salvatorelli Emanuela; Giorgio Minotti; Afeltra Antonella
Related Documents :
21502679 - Onset of heart failure determines the hepatic cell death pattern.
9434009 - Comparison of urodynamic investigations before and after posterior sagittal anorectopla...
16793729 - Combined protocol of cell therapy for chronic spinal cord injury. report on the electri...
8156669 - Should fusion accompany lumbar diskectomy? a medium-term answer.
14997969 - Progressive neurodegenerative disease in presumed spinal cord injury: case report of a ...
8667869 - Syringomyelia as a cause of body hypertrophy.
1160759 - The tourist as patient.
25194589 - Predicting duration of mechanical ventilation in patients with carbon monoxide poisonin...
10543279 - Medical thoracoscopic lung biopsy in interstitial lung disease: a prospective study of ...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-4-22
Journal Detail:
Title:  Autoimmunity reviews     Volume:  -     ISSN:  1873-0183     ISO Abbreviation:  -     Publication Date:  2011 Apr 
Date Detail:
Created Date:  2011-5-4     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101128967     Medline TA:  Autoimmun Rev     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2011. Published by Elsevier B.V.
Internal Medicine and Rheumatology, "N. Melli" Hospital, San Pietro, Brindisi, Italy; Integrated Research Center, Campus Bio-Medico University, Rome, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Mutagenesis and computer modeling studies of a GPCR conserved residue W5.43(194) in ligand recogniti...
Next Document:  The metabolic syndrome: The crossroads between rheumatoid arthritis and cardiovascular risk.